-

02:36:57 PM

LOGC Stock News

LOGC - LogicBio Therapeutics Inc

09/21/22 8:30 AM

Nasdaq : LOGC

clinical triallow float

LogicBio(R) Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic

RHEA-AI

negative

08/15/22 7:05 AM

Nasdaq : LOGC

earningslow float

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Interim data from SUNRISE trial in four pediatric patients showed detectable levels of ALB-2A biomarker demonstrating site-specific gene insertion and protein expression- Two of four patients demonstrated increasing ALB-2A levels over time, indicating expansion of edited hepatocytes carrying the

RHEA-AI

neutral

05/17/22 8:30 AM

Nasdaq : LOGC

conferenceslow float

LogicBio(R) Therapeutics to Present at H.C. Wainwright Global Investment Conference

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Global Investment

RHEA-AI

neutral

05/16/22 8:30 AM

Nasdaq : LOGC

earningslow float

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

RHEA-AI

positive

05/11/22 8:30 AM

Nasdaq : LOGC

conferenceslow float

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

- GeneRide (R) LB-401 preclinical data in HT1 demonstrated substantial and durable reduction of disease-related biomarkers-Proprietary AAV transfection process, harnessing mAAVRx (TM) system, showed 15- to 30-fold yield increase over standard processes-Improved downstream process resulted in increased

RHEA-AI

neutral

05/09/22 8:00 AM

Nasdaq : LOGC

low float

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

LogicBio(R) Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage company advancing a diversified pipeline of

RHEA-AI

neutral

03/23/22 4:30 PM

Nasdaq : LOGC

conferenceslow float

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

LogicBio (R) Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will present a company overview at the H.C. Wainwright Gene Therapy and Gene

RHEA-AI

neutral

03/08/22 4:05 PM

Nasdaq : LOGC

conferenceslow float

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

LogicBio (R) Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Frederic Chereau, will participate in a fireside chat during the Barclays Global Healthcare Conference

RHEA-AI

neutral

03/04/22 4:05 PM

Nasdaq : LOGC

earningslow float

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

LogicBio(R) Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates."At LogicBio, we are continuing to advance our mission to

RHEA-AI

neutral

02/02/22 6:00 AM

Nasdaq : LOGC

clinical triallow float

LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided an update on the LB-001 clinical development program. The U.S. Food and Drug Administration (FDA) has notified the company that its Phase 1/2 SUNRISE

RHEA-AI

neutral

1 2 3 4 5 6 Next

LOGC Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.logicbio.com
CeoFrederic Chereau
Security nameLogicBio Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees39
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address65 Hayden Ave
Address22Nd Floor
StateMassachusetts
CityLexington
Zip02421
CountryUS
Phone16172450399

About LogicBio Therapeutics Inc

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.